ClearNote Health launches enhanced Avantect Test for early pancreatic cancer detection
ClearNote Health announced the launch of its enhanced Avantect Pancreatic Cancer Test, which delivers significantly improved detection for patients at elevated risk of this disease. With a higher overall cancer detection sensitivity of 82.6% and specificity of 97.5%, the updated test empowers clinicians to identify signals of early-stage pancreatic cancer sooner, enabling more informed and timely clinical management decisions.
The enhanced Avantect Pancreatic Cancer Test uses an integrated, multianalyte and multiomic approach that relies on epigenomic 5-hydroxymethylcytosine (5hmC) patterns, genomic and genotyping information from cfDNA, and a glycan biomarker, combined with optimized machine learning algorithms. This approach has improved early-stage (I–II) sensitivity to more than 76%,, according to ClearNoth Health data on file. The enhanced test performance and user-friendly patient report allow clinicians to gain earlier insight into the likelihood of pancreatic cancer, offering additional context to inform clinical judgment alongside other diagnostic tools and clinical information.
Designed as a simple blood-based test, the Avantect Pancreatic Cancer Test is intended for patients at elevated risk of the disease, including those with known genetic predispositions, a family history of pancreatic cancer, or those age 50 or older who have been newly diagnosed with type 2 diabetes. By evaluating multiple cancer-associated signals together, ClearNote Health’s approach provides meaningful context for care discussions. The updated test will be used for the Surveillance of pAncreatic health aFter diabEtes Diagnosis (SAFE-D) study led by the NHS in the UK—one of the world’s largest projects evaluating pancreatic cancer detection in individuals with new-onset diabetes. The test is being incorporated into the international Pancreatic Cancer Early Detection (PRECEDE) Consortium, a global multi-center effort focused on advancing earlier diagnosis and risk-stratified screening for people with familial or genetic risk for pancreatic cancer.
The Avantect Pancreatic Cancer Test is currently available as a laboratory-developed test for people at high risk in the United States through ClearNote Health’s CAP/CLIA-certified laboratory, which is qualified to perform high-complexity clinical testing, and for patients outside the U.S. through ClearNote Health’s international laboratory partnership network spanning 70 countries. The test has not been cleared or approved by the U.S. Food and Drug Administration. ClearNote Health encourages patients to review their Avantect test results with their treating physician to better understand their significance and determine appropriate next steps in care.
ClearNote Health will share additional details about the improved Avantect Pancreatic Cancer Test, including the latest performance data, at the upcoming American Association for Cancer Research (AACR) and Digestive Disease Week (DDW) annual meetings.
